Magnolia Medical Technologies has recently introduced the Initial Specimen Diversion Device (ISDD), a patented, Class I device registered and listed with FDA that is indicated to reduce the frequency of blood culture contamination.
Benefits of utilizing ISDD to collect blood specimens for culture include:
Contact us to learn more about ISDD or to request additional information.
- Enhanced patient safety through reduction in unnecessary treatments including antibiotic therapies
- Improved patient outcomes due to informed treatment plans based on accurate initial diagnostic information
- Reduced unnecessary costs attributable to false positive blood cultures
- Increased bed availability and overall improvement in quality
Data about cost impacts of false positive diagnoses of septicemia, as well as links to a number of peer-reviewed medical journal publications that evaluate and analyze patient safety as well as hospital resource consumption attributable to contaminated blood cultures can be found via links above.